

BioMedica Diagnostics Inc.

P.O. Box 1030, 94 Wentworth Road, Windsor, NS B0N 2T0 Tel: (902) 798-5105

Fax: (902)

Mgmt: Dr. A.K. Kirumira Mktg: Mr. Ken Nelson
R&D: Dr. A.K. Kirumira Licn: Dr. A.K. Kirumira
kirumira@biomedicadiagnostics.com
www.biomedicadiagnostics.com
Est: 1991 - Private Staff #: 12

- Diagnostics
- Veterinary
- Engineering
- Instruments
- Research Group

Profile 13170:41-11

Formerly known as Octopus Diagnostics. Privately held medical biotech firm focusing on R&D & manufacturing of rapid diagnostic devices. With a dedicated focus on the needs of smaller labs & decentralized alternative testing sites; BioMedica markets portable analytical instruments supplied with preformatted "ready to use" diagnostic reagents. Target markets are medical, veterinary, military, environmental & food safety testing laboratories.

Products and Services

Instrument hardware and software development, chemiluminescence based assays. Synthetic diagnostic molecular mimics. Immobilized "Dry Chemistry", Diagnostic Systems, Enhanced Immunodiagnostic and DNA hybridization signalling. Portable diagnostic instrumentation, cell/sperm viability testing kits, clinical chemistry, blood coagulation analyzers and reagents.

Biomira Inc.

2011 - 94 Street, Edmonton, AB T6N 1H1 Tel: (780) 490-2801
(877) 234-0444

Fax: (780)

Mgmt: Dr. Alex McPherson Mktg: Mr. Robert Aubrey
R&D: Dr. Peter Emtage Licn: Mr. Robert Aubrey
baubrey@biomira.com
www.biomira.com
Est: 1985 - Public 2005 Rev: 0.00 Staff #: 110

- Therapeutics - H
- Peptides
- Antibodies-Ther
- Vaccines-Human

Profile 1002:11-21

Stock Symbol: TSX: BRA Nasdaq: BIOM

Biomira Inc. is a product focused biotechnology company applying its proprietary immunology and organic chemistry technologies for the development of therapeutic cancer vaccines. Therapeutic cancer vaccines belong to a new generation of experimental cancer treatments that may stimulate the patient's immune system to recognize the cancer. Designed to be highly specific to cancer cells, such therapies may have fewer effects on other cells in the patient's

Products and Services

BLP25 Liposome Vaccine - synthetic MUC1 peptide vaccine is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. In Sept 2004, the FDA granted fast track status to the investigation of L-BLP25 for its proposed use in the treatment of NSCLC. Phase III study expected to start in 2006.

BioMS Medical Corporation

6030 - 88th Street, Edmonton, AB T6E 6G4

Tel: (780) 413-7152
(866) 701-6033

Fax: (780)

Mgmt: Mr. Kevin Giese Mktg: Mr. Ryan Giese
R&D: Dr. Kenneth G. Warren Licn: Ms. Colleen Smecko
info@biomsmedical.com
www.biomsmedical.com
Est: 2000 - Public

- Therapeutics - H
- Drug Developm't
- Stem Cells

Profile 16078:11-21

Stock Symbol: TSX: MS

A biopharmaceutical company dedicated to the development and commercialization of innovative therapies. Targeted diseases include multiple sclerosis.

Products and Services

BioMS is developing MBP8298 for treatment of multiple sclerosis (MS). MBP8298 is based on 25 years of ground-breaking research, and is licensed to BioMS on an exclusive worldwide basis from the University of Alberta. MBP8298 has undergone Phase I and II human clinical trials, received approval from Health Canada to initiate Phase II/III clinical trial to investigate use of therapeutic as treatment for SPMS.

Bioniche Life Sciences Inc.

P.O. Box 1570, Belleville, ON K8N 5J2

Tel: (613) 966-8058
(800) 265-5464

Fax: (613)

Mgmt: Mr. Rick Culbert Mktg: Ms. Marylynn David
R&D: Dr. Dragan Rogan Licn:
info@bioniche.com
www.bioniche.com
Est: 1979 - Public 2005 Rev: 40.00 Staff #: 235

- Therapeutics - H
- Veterinary
- AgBio-Animal

Profile 684:11-21

Stock Symbol: TSX: BNC

Bioniche is a fully integrated Canadian bio-pharma company engaged in R&D, production and commercialization of proprietary technologies for human & animal health markets worldwide. Bioniche Therapeutics is responsible for scientific disc in-vitro & in-vivo pre-clinical R&D of human health products derived from proprietary technologies; clinical studies, regulator submission and commercialization of technologies.

Products and Services

Suplasyn® for treatment of Osteoarthritis; Cystistat® for treatment of Interstitial Cystitis, a painful, debilitating bladder condition. Primary focus of R&D programme is cancer, immunomodulation and inflammation.